General Bone Cancer

Xgeva Safe and Effective for Giant Cell Tumor of the Bone (08-6-2013)

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant cell tumor of the bone. In fact, 96 percent of patients... Continue Reading

Xgeva Approved for Treatment of Giant Cell Tumor of the Bone (07-17-2013)

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant cell tumor of bone (GCTB) is a rare, aggressive, benign... Continue Reading

Xgeva Reduces Giant-cell Tumor of the Bone (10-2-2012)

Xgeva® (denosumab) significantly reduced or eliminated tumor giant cells in patients with giant-cell tumor of the bone and also increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research. Giant cell... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (03-26-2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Xgeva Delays Onset of Bone Metastases (09-27-2011)

Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. These results were presented at the 2011 European Multidisciplinary Cancer Conference. Androgen... Continue Reading

Stay on Top of Your Family History of Cancer (07-15-2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Denosumab Active Against Giant Cell Tumor of Bone (02-11-2010)

In a Phase II clinical trial, denosumab produced high rates of tumor response among patients with recurrent or unresectable giant cell tumors of bone. These results were published in Lancet Oncology. Denosumab is an investigational drug that targets... Continue Reading

Denosumab Produces Promising Results Against Giant Cell Tumor of the Bone (06-5-2009)

Denosumab Produces Promising Results Against Giant Cell Tumor of the Bone In a Phase II clinical trial, 86% of patients with giant cell tumor of the bone responded to treatment with the investigational targeted therapy denosumab. These results were presented... Continue Reading

Denosumab Reduces the Risk of Bone Fractures (03-8-2009)

Denosumab Reduces the Risk of Bone Fractures According to the results of a Phase III clinical trial, treatment with denosumab significantly reduces the risk of vertebral and hip fractures among postmenopausal women with osteoporosis. These results were... Continue Reading